Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Lidco Group Plc LSE:LID London Ordinary Share GB0030546849 ORD 0.5P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -2.4% 6.10 852,019 16:09:12
Bid Price Offer Price High Price Low Price Open Price
6.00 6.20 6.25 5.75 6.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 7.55 -1.21 -0.42 15
Last Trade Time Trade Type Trade Size Trade Price Currency
16:33:06 O 500,000 6.50 GBX

Lidco (LID) Latest News

More Lidco News
Lidco Investors    Lidco Takeover Rumours

Lidco (LID) Discussions and Chat

Lidco (LID) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-10-28 17:15:006.50500,00032,500.00O
2020-10-28 17:15:005.75600,00034,500.00O
2020-10-28 16:33:076.0050,0003,000.00O
2020-10-28 16:10:096.196,462400.00O
2020-10-28 16:08:336.1980,7754,999.97O
View all Lidco trades in real-time

Lidco (LID) Top Chat Posts

DateSubject
28/10/2020
08:20
Lidco Daily Update: Lidco Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker LID. The last closing price for Lidco was 6.25p.
Lidco Group Plc has a 4 week average price of 5.75p and a 12 week average price of 5.75p.
The 1 year high share price is 10.75p while the 1 year low share price is currently 3.75p.
There are currently 244,174,908 shares in issue and the average daily traded volume is 816,495 shares. The market capitalisation of Lidco Group Plc is £14,894,669.39.
22/10/2020
11:47
effortless cool: It was a bit of a struggle with liquidity, but I have finally completed exiting from my holding. Having analysed the figures and the prospects, I don't believe that this business has any value at all as a stand-alone entity. The brief flurry of optimism from a COVID-driven 2020 H1 profit has been suppressed by the loss that will follow in a mediocre H2. Further, it is now apparent that most of the H1 growth came from non-HUP sales and deferred revenue at end of the period was very disappointing, standing 27% below the position at Jan 2020. The outlook does not seem sufficiently positive to drive revenue sharply higher, and I forecast further losses in 2021 H1 and 2021 H2. The business could be profitable as a unit within a bigger player, since that would allow a considerable reduction in operating expenses and the big hope must be that its IP has sufficient value that someone may buy it with a view to committing a big marketing budget to drive market share. Management and broker presentations have emphasised the value created for shareholders through other transactions in the sector. My concern here is that this suggests that the sector is already crowded and, since LID has been around and vulnerable for some time, perhaps indicates that big sector players do not see great value in the LID IP. In any case, I don't consider holding onto to something in the hope that some other business might take it over to be a viable investment strategy. I have taken a sizeable loss here; I hope that continuing shareholders fare better.
13/10/2020
06:18
molatovkid: Excellent results! I agree with the double figure share price!
25/8/2020
19:24
multibagger: Re profit - we may creep over the line and may be profitable this financial year (here's hoping anyway)and some considerations that help me head to this tentative conclusion. *We have had unprecedented Q1 and a strong Q2 trading revenue wise *We have moved location from a Central London manufacturing, warehousing and office base recently - so possibly some savings on rent and associated costs *Countries across the world are slowly opening up and that will allow our directly employed sales people and sales partners to make face to face visits *Our own NHS may be buying more LID equipment and its use/value in front line clinical care would have been shared across clinical networks *Capital restructuring and legal costs re share premium - costed circa £30k in another company that I am invested in- why would LID spend that money to be able to pay dividends, if there is no real profit to pay the dividends from in the near future ? All in all, the market may warm to our performance in due course and that could attract a takeover bid. 10 Sep 2019: Baxter acquires Cheetah (competitor with 10% US market share, revenues approx $30m pa, about 6x revenues, and loss making) for about $190m upfront and a further $40m contingent on performance. Using the above as a ball park/guideline, and if we hit £10m annual LID revenues, that could translate to a buyout price of LID at approx 24.5p per share. Remember Cheetah was loss making - so if are profit making when we get taken out, I suppose that could attract a further premium. Anyway, just my musings, as always best DYOR :)
24/8/2020
06:57
multibagger: Given the recent interest in any listed company healthcare related, I guess we could see some momentum traders arrive. LID is pretty tightly held, so the buying over the last week or so with an increase in share price could have been a sign of good things to come ! Let's see what the day brings, but I expect a fair bit of interest ;) Good luck all !
24/8/2020
06:13
multibagger: An exceptional financial performance in these challenging times....and also the pride of owning a tiny fraction of a business that genuinely makes a difference to people's lives !! Well done to Matt and the team ! I wouldn't be surprised to see a share price spike by about 2- 2.5p today, or even more, given it is pretty tightly held :) Mon, 24th Aug 2020 07:00 RNS Number : 8874W LiDCO Group Plc 24 August 2020 LiDCO Group Plc ("LiDCO" or the "Company") Trading update Record first half performance with LiDCO product revenue up by 83% LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close trading update for the six months ended 31 July 2020 ("H1"), ahead of its interim results which are expected to be announced on 13 October 2020. LiDCO continues to support healthcare providers to improve patient outcomes while reducing the cost of care, and in H1 successfully responded to exceptional demand related to the COVID-19 pandemic to achieve a record first half performance. International experts treating COVID-19 patients have concluded that hemodynamic optimisation plays a major role in the management of the complex interaction of respiratory and cardiovascular factors. LiDCO provides a market leading solution, via either the arterial line or non-invasively, to support the diagnostic and therapy-guiding functional hemodynamic tests as recommended by COVID-19 frontline experts and global guidelines. In H1, total revenues (including third party products) increased by 75% to £6.2m (2019: £3.5m) with LiDCO product revenues up 83% to £6.1m (2019: £3.3m). This exceptionally strong sales growth was due to increased demand for advanced hemodynamic monitors as healthcare providers expanded critical care services to deal with the COVID-19 pandemic, primarily in the UK where LiDCO is market leader. As a result of the strong top line growth, LiDCO achieved net positive cash inflow of £1.8m in H1 (2019: £0.5m net outflow). The Company had £3.1m of cash as at 31 July 2020 and has no borrowings. Given the strong cash inflow in H1, the Board decided not to continue to take advantage of the UK Government's option to defer VAT payments and brought these payments up to date by 31 July 2020. As widely reported, there has been a significant postponement in the number of elective surgery procedures during the pandemic. Over the last three years, the Company's key commercial strategy has been to sign up customers for its Software as a Service (SaaS) HUP business model, in which customers pay an annual license fee that is independent of the number of patients treated. HUP customers continue to benefit from this model by not having to pay any extra costs to redeploy LiDCO haemodynamic monitors from use in elective surgeries to providing critical care to COVID-19 patients. In parallel, the Company continues to benefit from the predictable, contracted HUP revenue stream, as well as additional demand from customers taking out new HUP contracts. In the period, HUP revenues increased by 83% to £1.5m (2019: £0.8m). Where customers remained on the pay per patient model, the postponement of elective surgeries led to a reduction in consumable sales by around one fifth compared to H1 2019, but the additional HUP revenues more than offset this reduction. Total LiDCO product recurring revenue in H1 was up 12% to £2.8m (2019: £2.5m). Geographically, LiDCO product sales grew by 157% in H1 in the UK to £4.1m (2019: £1.6m). UK hospitals invested in growing their critical care provision by acquiring new monitors to meet anticipated needs. Distribution markets also grew, by 41% to £1.2m (2019: £0.8m), with the greatest demand coming from Asia. In the USA, hospitals were focussed on preparing for or dealing with COVID-19, which suppressed capital sales and the finalisation of a number of potential new HUP contracts, although recurring revenues grew slightly compared with the first half of last year. This increase was driven by the carry-through from strong growth in HUP contracts during the prior year, which offset declines in per patient disposables due to the reduced number of elective surgeries in H1. Around the globe, the Group is actively supporting healthcare providers managing many different stages of the COVID-19 pandemic, including those preparing for a second wave. In the USA, the world's largest healthcare market, elective surgeries started to recommence during Q2 and LiDCO's commercial personnel were able to resume visits to some customers. Further local lockdowns have, however, limited efforts to close the pipeline of new HUP opportunities, which are now targeted to close in H2. During H1, the Company sold 230 monitors compared with 111 units in H1 2019. A number of these monitors were sold with HUP licences, and, as of the 31 July 2020, the global installed base of HUP monitors with annual licences was 327 units (31 July 2019: 216 units). Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "I am incredibly proud of how the entire team has been able to respond quickly to the needs of our customers during these challenging times and ensure that LiDCO plays its part in supporting hospitals in treating COVID-19. The strong start in H1 combined with the forward visibility of HUP revenues and enlarged installed base, gives the Board significant confidence as we look forward."
30/4/2020
10:38
vega44: LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring solutions, will be carrying out a live webinar, delivered by Matt Sassone, CEO and Tim Hall, CFO, to update shareholders on the business and the current growth strategy. The webinar will be hosted by ShareSoc on Tuesday 5 May 2020. LiDCO Group will be the sole company presenting. ShareSoc is an organisation dedicated to supporting individual private shareholders ensuring that they have a voice and better access to information on the companies they invest in. The event will commence at 11.00am on Tuesday 5 May 2020. Further details of the event, along with a registration form, are available here: hxxps://www.sharesoc.org/events/sharesoc-webinar-with-lidco-lid-5-may-2020/ No new material information will be disclosed during the event.
09/3/2020
07:03
multibagger: Wish all affected by Corona Virus a full recovery....LID playing a role. RNS Number : 3551F LiDCO Group Plc 09 March 2020 LiDCO Group Plc ("LiDCO" or the "Company") Increased sales demand from China in response to COVID-19 LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring company, announces that its Chinese distribution partner, Beijing Gloryway Medical Company, has recently sold a small number of monitors in Wuhan, China as a direct response to the COVID-19 virus outbreak. A number of LiDCOrapid monitors had already been installed in the city prior to the COVID-19 outbreak. The recent purchase is to provide additional Intensive Care monitoring capabilities in order to treat the most acute cases of the infection. The transaction was able to be arranged without LiDCO or our distributors’ staff visiting Wuhan. LiDCO has fully assessed the impact of the outbreak on its supply chain and is satisfied that its inventory levels and forward purchases of monitors would support a certain amount of above forecast demand should it arise in areas affected by Covid-19. The Company is in communication with healthcare institutions in a number of the affected areas and is prepared to be flexible in its approach in order to meet any short-term increased monitoring needs. Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: “The proportion of patients who are admitted to Intensive Care following COVID-19 infection remains low, however, there is significant clinical evidence that the use of advanced hemodynamic monitoring for patients in intensive care is clinically beneficial. Whilst the Board doesn’t anticipate changing expectations at this time, the Company is prepared to support customers should they face an increased demand for intensive care.”
05/11/2019
07:02
multibagger: Excellent news !! 05 November 2019 LiDCO Group Plc ("LiDCO" or the "Company") Latest monitor launched in China LiDCOrapid(v3) monitor launches in the second largest healthcare market in the world LiDCO (AIM: LID), the hemodynamic monitoring company, announces that the LiDCOrapid(v3) monitor, LiDCO's latest cardiac output monitor with non-invasive technology has been launched in China at the 27(th) Annual Meeting of the Chinese Society of Anesthesiology (CSA2019), which was held in Hangzhou. This follows the Company receiving Chinese Food and Drug Administration ("CFDA") approval in July 2019. The Company's hemodynamic LiDCOrapid(v3) monitor product will be sold via LiDCO's distribution partner, Beijing Gloryway Medical Co., Ltd ("Gloryway"). Gloryway is a leading medical device sales group specialising in anaesthesia and patient monitoring with a direct commercial presence in China. Uniquely LiDCO will be the only western supplier of hemodynamic monitoring solutions that is manufacturing its product locally in China. This could be a key differentiator as the vast majority of the 22,000 hospitals in China can only procure domestically manufactured products. China is the second largest healthcare market in the world with a five-year compound annual growth rate by value of 17% compared with 4% in the United States(1) . Over the last few years an increasing number of clinical studies originating from China have been published, reinforcing the positive impacts of hemodynamic monitoring proven in studies elsewhere in the world. This is helping to drive adoption of hemodynamic monitoring technologies in China, which represents a substantial opportunity for the Company. The Board anticipates that this launch will be a key contributor to the Company's future international sales growth. Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "We have worked with our distribution partner, Gloryway, for a number of years. This launch is strategically important for LiDCO and we believe that this could lead to significant sales growth in this rapidly growing market for hemodynamic monitoring." (1) - Major healthcare markets defined as top five global markets by the World Health Organization. 6/30/2018
07/9/2019
04:59
multibagger: Company Website: Http://www.lidco.com Total Equity (28 Feb 2019): 244,174,908 shares Major Share Holders: Http://www.lidco.com/investors/shareholder-information/ BoD/Director Purchases 2019: Mr T Hall, CFO 26 Mar 19 100k Total Holdings: 100k 0.041% Mr P Grant, Chairman 26 Mar 19 200k 15 Oct 19 244k Total Holdings: 944,163 0.387% Mr P Cooper, NED 26 Mar 19 100k 29 Mar 19 250k 01 Apr 19 650k Total: 2,666,667 1.092% Mr J Wetrich NED 18 Nov 19 19.9k Total: 19,900 0.008% Investor Presentation March 2019 Http://www.lidco.com/wp-content/uploads/2019/03/March-19-Results-Presentation.pdf Growth and Innovation Forum,11 Feb 2020 Http://www.lidco.com/wp-content/uploads/2020/02/Growth-Innovation-London-Feb-20-v2.pdf Regulator Approved In The Following Countries: UK - LID direct marketing EU (EU base/warehousing established in Netherlands as part of Brexit Planning) USA - LID direct marketing Japan - Master Distributorship (MD) through Merit China - MD through Beijing Gloryway Medical South Korea - MD through Globaluck Ltd Taiwan - MD through Fieldman and for South East Asia Singapore Indonesia Saudi Arabia - MD through Razan Medical for Middle East Latin America (regulatory submissions made in Brazil and Colombia) - Elysian Fields is Master Distributor Lidco also does 3rd party distribution in the UK for Antmed - pressure transducers Xavant - nerve stimulator Maicuff - Disposable NIBP cuffs Global market is circa $250m per annum, with a total market being potentially $2 billion per annum. 10 Sep 2019: Baxter acquires Cheetah (competitor with 10% US market share, revenues approx $30m pa, about 6x revenues, and loss making) for about $190m upfront and a further $40m contingent on performance. On forecast 2019/20 LID revenues, that would translate to a buyout price of LID at approx 17p per share. Basic Introduction to Lidco: Lidco is an UK headquartered, haemodynamic monitoring company (real time monitoring of various blood parameters like heart rate, blood pressure, stroke volume etc) which helps doctors manage patient's cardiac function during high risk surgery and critical illness. Haemodynamic monitoring improves patient outcomes in areas such as (backed up by extensive independent clinical papers, NICE guidance and Consensus statements/ protocols) High Risk Elective Surgery - Colorectal, Vascular, Hip Replacement, Liver Resection, Oesophagectomy Emergency Surgery - Cardiac, Abdominal, Caesarean, emergency laparotomy Intensive care - high risk patients in ICU, Septic shock in ICU Reduces patient deaths Reduces length of stay Fewer complications Cost savings
20/8/2019
06:03
multibagger: LiDCO Group Plc 20 August 2019 LiDCO Group Plc ("LiDCO" or the "Company") Trading update & Notice of results LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following trading update for the six months ended 31 July 2019. LiDCO product revenues in the half year were up 10% compared with H1 last year to GBP3.33m (2018: GBP3.02m), slightly above the Board's expectations. The strong year on year sales growth in H1 was notwithstanding the continuing transition of more of the largest UK customers to the Group's Software as a Service ("SaaS") High Usage Programme ("HUP") business model, which has the effect of deferring revenue recognition. HUP revenues in H1 grew 119% to GBP0.80m (2018: GBP0.37m) contributing to the overall performance of the business in the period. To date the Company now has 243 HUP monitors (31 January 2019: 164) placed in the market that will generate annualised revenues of GBP2.1m. US revenues were up 47% (42% on a constant currency basis) to GBP0.90m (2018: GBP0.61m), with the growth being driven by the continued success of the HUP offering enabling the Company to take share in this large and growing market by targeting high volume users of advanced hemodynamic monitoring. In the UK, LiDCO product revenues declined by 8% to GBP1.61m (2018: GBP1.76m) due to the timing of certain large orders and the Company's decision to transition another four of its largest customers to the HUP business model. The impact of these two factors is estimated to have reduced H1 revenue by GBP0.2m. The strategy, to actively convert UK customers to the SaaS business model, has a transitional impact on revenues as these customers typically de-stock inventory ahead of transitioning to HUP. Overall the Company believes that it is maintaining its leading share of the UK hemodynamic monitoring market. Outside of the Group's two direct markets, sales to distributors grew by 27% to GBP0.83m (2018: GBP0.65m). The recently announced regulatory approvals of the latest hemodynamic LiDCOrapid(v3) monitor in both China and South Korea, and the appointment of a master distributor in Latin America, are expected to contribute to further growth in the second half of the year. Total revenues (including third party products) were down 4% to GBP3.51m (2018: GBP3.64m) as a result of the previously announced termination of the Argon Critical Care distribution contract which contributed GBP0.63m in H1 2018 but just GBP0.16m in H1 2019. Adjusting for all third party revenue, including the effect of this terminated contract, gives the underlying growth of 10% for LiDCO products as stated above. Net cash outflow in H1 was down 57% to GBP0.53m (2018: GBP1.22m). This figure is before the receipt of an expected R&D tax credit of GBP0.19m (2018: GBP0.13m), normally received in H1 but deferred into H2 this year. The Company had GBP1.19m of cash as at 31 July 2019 and remains debt free. As set out in the Annual Report and Accounts for 2018/19, the Board believes that LiDCO retains the appropriate strength in its balance sheet to deliver its strategic objective of creating a profitable business with good forward visibility from cash-generative, recurring SaaS revenue streams. The Company intends to announce its interim results on 15 October 2019. Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "It's been a good start to the year that has enabled us to transition more UK customers to HUP. In the US we are continuing to gain success from a comparatively small sales presence, which demonstrates the potential of the HUP business model. With HUP gathering more momentum, we are focussed on achieving a strong second half performance as the business moves progressively towards breakeven."
Lidco share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
LID
Lidco
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201029 05:47:55